Results 121 to 130 of about 909,683 (265)

Hypolacrimia and Alacrimia as Diagnostic Features for Genetic or Congenital Conditions. [PDF]

open access: yesInvest Ophthalmol Vis Sci, 2022
Willems M   +5 more
europepmc   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

open access: yesMolecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li   +10 more
wiley   +1 more source

CIDP With and Without Monoclonal Gammopathy of Undetermined Significance (MGUS): Comparison of Clinical Phenotype, Diagnostic Features, and Treatment Response. [PDF]

open access: yesJ Peripher Nerv Syst
van Veen R   +16 more
europepmc   +1 more source

Diagnostic features of type II fibrinoid leukodystrophy (Alexander disease) in a juvenile Beagle dog. [PDF]

open access: yesJ Vet Intern Med, 2023
Vandenberghe H   +6 more
europepmc   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

open access: yesMolecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff   +11 more
wiley   +1 more source

Clinical and Diagnostic Features of Feline Epilepsy: Distribution of Seizure Types and Associated Factors. [PDF]

open access: yesAnimals (Basel)
Jankauskas M   +5 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy